FDA OKs Sarepta study of new immune suppression approach with Elevidys; Gilead buys preclinical TREX1 program

CellA skin-hypothalamus axis couples heat stress and metabolic dysfunction

CellThe evolution of high-order genome architecture revealed from 1,000 species

CellSomatic cancer variants enriched in Alzheimer’s disease microglia-like cells drive inflammatory and proliferative states

CellPyruvate is a natural suppressor of interferon signaling by inducing STAT1 protein pyruvylation

CellMechanism-guided identification of antidepressant G protein-coupled receptor drug targets

BDArea Softball: PRB gets 2 wins - Brainerd Dispatch

FierceBiotechWCG acquires The Contract Network in bid to streamline clinical trial execution

RecursionRecursion Pharmaceuticals director Gibson sells $144,400 in stock By Investing.com - Investing.com Canada

RecursionRecursion Pharmaceuticals (NASDAQ: RXRX) director sells 40K shares under plan - Stock Titan

Recursion[SCHEDULE 13G/A] RECURSION PHARMACEUTICALS, INC. Amended Passive Investment Disclosure - Stock Titan